GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.

导出 OA

翻译打印收藏纠错

作者： P,Hadji ^[1] ; I,Kyvernitakis ^[2] ; P H,Kann ^[3] ; C,Niedhart ^[4] ; L C,Hofbauer ^[5] ; H,Schwarz ^[6] ; A A,Kurth ^[7] ; F,Thomasius ^[8] ; M,Schulte ^[9] ; M,Intorcia ^[10] ; E,Psachoulia ^[10] ; T,Schmid ^[9]

作者单位： Department of Bone Oncology, Endocrinology, and Reproductive Medicine, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488, Frankfurt am Main, Germany. hadji.peyman@khnw.de. ^[1] Department of Bone Oncology, Gynecological Endocrinology and Reproductive Medicine, Nordwest Hospital, Frankfurt am Main, Germany. ^[2] Centre for Internal Medicine - Endocrinology & Diabetes, Philipps University of Marburg, Marburg, Germany. ^[3] Gemeinschaftspraxis, Heinsberg, Germany. ^[4] Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine 3 and Center for Healthy Aging, TU Dresden Medical Center, Dresden, Germany. ^[5] Facharztpraxis für Orthopädie und Physiotherapie, Freudenstadt, Germany. ^[6] Themistocles Gluck Hospital, Ratingen, Germany. ^[7] Department of Bone Oncology and Osteoporosis Center, Krankenhaus Nordwest, Frankfurt am Main, Germany. ^[8] Amgen (Europe) GmbH, Munich, Germany. ^[9] Amgen Europe, Zug, Switzerland. ^[10]

关键词 Bisphosphonates Compliance Denosumab Osteoporosis Persistence